Substandard medicines huge threat to health in developing world

Alison Bird/USAID

Women wait by their sick babies while they receive treatment, in the municipal hospital of M'banza Congo, Zaíre province. Pregnant women and children under age 5 in Angola are among the groups most vulnerable to the scourge of malaria.

Article Highlights

  • Up to 15% of all drugs bought in African cities and 7% in Indian cities failed basic quality testing.

    Tweet This

  • 40% of malaria drugs bought in the two largest West African cities have insufficient active ingredient.

    Tweet This

  • Are drug manufacturers boosting profits by cutting corners in the manufacturing process of drugs supplied to Africa?

    Tweet This

  • To stop substandard medicines, European donors must pressure Beijing & New Delhi to put their regulatory houses in order.

    Tweet This

 

European donors have made great efforts in recent years to improve the supply of medicines for diseases affecting the world’s poorest people, particularly malaria, tuberculosis (TB) and other deadly infections. But what if a small but significant proportion of these medicines are inferior? It would potentially undermine donor efforts and pose a grave threat to public health.

My team of researchers has carried out a significant study into drug quality. Over the past four years, we purchased 2652 samples of antimalarials, antibiotics and TB drugs from pharmacies in 19 cities across 17 developing and middle-income countries. The results are alarming: up to 15% of all drugs bought in African cities and 7% in Indian cities failed basic quality testing. In more detailed analysis of some of the malaria drugs, 40% of those bought in the two largest West African cities have insufficient active ingredient.

If a drug used to treat these diseases is not made to high standards, a sick patient is unlikely to recover and it increases the chance of malaria parasites or TB bacteria developing resistance to the treatment. This has the potential to render entire classes of medicines useless, making malaria or TB much more expensive to treat, and in a few instances untreatable with currently available medicines. Given that 8,8-million people contracted TB in 2010, and at least 240-million malaria, the public health consequences are dire.

Some of the substandard drugs we identified were most likely counterfeits.

But many more were made by local African, Indian or Chinese companies, but without the proper oversight of a competent government drug regulatory authority. Up to 25% of such drugs manufactured in Africa, 16% of those made in China and 4% of Indian drugs failed our testing, compared with 1,7% of those made in the European Union and the US.

More disturbingly, a small but significant number of poor-quality drugs we found had been quality-assured by the World Health Organisation (WHO), which does a pseudo-regulatory job for countries with little capacity. While drugs approved by the WHO are generally high quality, we found that some antimalarials, manufactured in China, were quite often inferior. Nearly 18% of the WHO-approved Chinese products we tested did not reach required standards, contrasting with a still worrying 2,4% failure rate of Indian-made WHO-approved products.

There are several reasons this may be happening. The most acute problem is with artemisinin combination therapies, a modern class of malaria drug.

One explanation is that recent global shortages of artemisinin (the main natural ingredient in the drug, derived from the sweet wormwood plant) have led to supply problems, which has resulted in many companies being forced to cut corners in order to deliver their medicines to agreed timetables. Another explanation is more sinister. It may well be that certain Chinese (and to a lesser extent Indian) drug manufacturers are boosting profits by cutting corners in the manufacturing process of drugs they supply to Africa. As the drug regulatory failures in India and China are well known, this is not so difficult for unscrupulous manufacturers to get away with.

In April, the Indian drug regulator was heavily criticised by the Indian parliament for colluding with drug manufacturers. Chinese authorities do not allow proper access to inspectors from overseas, resulting in audit reports indicating that more than a third of Chinese ingredients come from unknown sources.

Many African countries do not have the expertise or money to monitor properly the quality of drugs in their own markets and the WHO does not have the budget or ability to monitor the drugs it has approved once they have made it onto the market.

European donors must pressure Beijing and New Delhi to put their regulatory houses in order. After all, EU taxpayers pay for many of these Chinese and Indian drugs on behalf of the poor in Africa. Donors should expose and combat the double standard of companies exploiting weak oversight to sell poor-quality products to lower-income markets. In the face of such a threat to public health, inaction is not an option.

Dr Roger Bate is a resident scholar at the American Enterprise Institute and the author of Phake: The Deadly World of Falsified and Substandard Medicines.

 

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate
  • Roger Bate is an economist who researches international health policy, with a particular focus on tropical disease and substandard and counterfeit medicines. He also writes on general development policy in Asia and Africa. He writes regularly for AEI's Health Policy Outlook.
  • Phone: 202-828-6029
    Email: rbate@aei.org
  • Assistant Info

    Name: Katherine Earle
    Phone: (202) 862-5872
    Email: katherine.earle@aei.org

What's new on AEI

image The Census Bureau and Obamacare: Dumb decision? Yes. Conspiracy? No.
image A 'three-state solution' for Middle East peace
image Give the CBO long-range tools
image The coming collapse of India's communists
AEI on Facebook
Events Calendar
  • 21
    MON
  • 22
    TUE
  • 23
    WED
  • 24
    THU
  • 25
    FRI
Wednesday, April 23, 2014 | 12:00 p.m. – 1:30 p.m.
Graduation day: How dads’ involvement impacts higher education success

Join a diverse group of panelists — including sociologists, education experts, and students — for a discussion of how public policy and culture can help families lay a firmer foundation for their children’s educational success, and of how the effects of paternal involvement vary by socioeconomic background.

Thursday, April 24, 2014 | 12:00 p.m. – 1:30 p.m.
Getting it right: A better strategy to defeat al Qaeda

This event will coincide with the release of a new report by AEI’s Mary Habeck, which analyzes why current national security policy is failing to stop the advancement of al Qaeda and its affiliates and what the US can do to develop a successful strategy to defeat this enemy.

Friday, April 25, 2014 | 9:15 a.m. – 1:15 p.m.
Obamacare’s rocky start and uncertain future

During this event, experts with many different views on the ACA will offer their predictions for the future.   

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled today.
No events scheduled this day.